Mirati Therapeutics, Inc.
http://mirati.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mirati Therapeutics, Inc.
Mirati Forges Path Forward For Adagrasib In mNSCLC Despite Lukewarm Preliminary Early-Stage Data
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.
Canon To Launch US-Based Medical Imaging Company In January 2023
Japan-based Canon plans to launch a US-based medical imaging company near Cleveland to strengthen its US presence and competitiveness in the marketplace.
Cordis Looks To Regain Previous Innovation Edge With Drug-Eluting Balloons
Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.
Speculation Grows On Potential Big Pharma Buyout Of Mirati
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- MethylGene Inc.